By identifying markers linked to tumor aggressiveness, such as TFE3 and Vimentin, clinicians can tailor monitoring and therapeutic interventions, optimizing outcomes for patients with this rare RCC subtype [52]. This evidence concerns the gene VIM and neoplasm.